COMMUNIQUÉS West-GlobeNewswire

Sharps Technology, Inc. Announces Stockholders’ Approval of Reverse Stock Split Ratio and Effective Date

14/10/2024 - 14:00

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe [...]

Integra LifeSciences to Host Third Quarter 2024 Financial Results Conference Call on November 4, 2024

14/10/2024 - 14:00

PRINCETON, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2024 financial results on Monday, [...]

HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024

14/10/2024 - 14:00

Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFR CT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFR CT diagnostic pathway to be discussed in six presentations New data build [...]

Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

14/10/2024 - 14:00

ADELAIDE, Australia and CAMBRIDGE, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric [...]

MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

14/10/2024 - 14:00

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended [...]

Boundless Bio Announces Departure of Chief Financial Officer

14/10/2024 - 14:00

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]

MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6

14/10/2024 - 14:00

MDxHealth to Present Third Quarter 2024 Financial Results and Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM [...]

Helio Genomics’ Methylation Model Score for Assessing Prognosis and Treatment Response in Patients with Hepatocellular Carcinoma Presented as Top Abstract at the 2024 San Antonio Liver Cancer Symposium

14/10/2024 - 14:00

IRVINE, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, showcased [...]

Biora Therapeutics to Reveal 00-Size BioJet™ Device at the 14th Annual Partnership Opportunities in Drug Delivery Meeting

14/10/2024 - 14:00

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced that Adi Mohanty, CEO of Biora Therapeutics, will present on [...]

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14/10/2024 - 14:00

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting [...]

Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024

14/10/2024 - 13:35

MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

14/10/2024 - 13:31

-- Highlights include data from clinical, non-clinical and microbiology programs, real-world patient use and a five-year microbiologic surveillance study of NUZYRA BOSTON, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Paratek [...]

ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024

14/10/2024 - 13:30

WINSTON-SALEM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), [...]

Codexis Announces New Employment Inducement Grants

14/10/2024 - 13:05

REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of [...]

Kraig Biocraft Laboratories Nears Completion of Largest Production Batch of Parental Line Spider Silk Silkworms

14/10/2024 - 13:05

This Milestone marks the Achievement of True Commercial-scale Levels of Parental Strain Production ANN ARBOR, Mich., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or " [...]

Fortrea Announces Date for Third Quarter 2024 Financial Results and Conference Call

14/10/2024 - 13:00

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2024 financial [...]

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)

14/10/2024 - 13:00

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO ® (berotralstat) [...]

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

14/10/2024 - 13:00

14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data [...]

GEn1E Lifesciences Publishes Breakthrough Research Unveiling Novel Mechanism of Action of Dual Signal Modulators for Anti-inflammatory and Endothelial-Stabilizing Therapies

14/10/2024 - 12:02

PALO ALTO, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- GEn1E Lifesciences, a clinical-stage Phase 2 company, and a leading innovator in precision therapies for inflammatory and rare diseases, with a strong partnership [...]